Drug Trial Radar · NCT07230106
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Conditions
- Prostate Cancer
Interventions
HS-20093 for InjectionDrug
HS-20093 for injection.
SHR3680 TabletDrug
SHR3680 tablet.
Abiraterone TabletDrug
Abiraterone tablet.
SHR2554 TabletDrug
SHR2554 tablet.
Enzalutamide TabletDrug
Enzalutamide tablet.
Darotamine CapsuleDrug
Darotamine capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: 6-month undetectable Prostate Specific Antigen (PSA) rate.Time frame: 6 months.
- Cohort 2: Prostate Specific Antigen (PSA) response rate.Time frame: About 2 years.
- Cohort 2: Adverse events (AEs).Time frame: About 2 years.
- Cohort 2: Dose-limiting toxicity (DLT).Time frame: About 28 days.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.